Clinical analysis

Why your lab should upgrade to enzymatic or compensated Jaffé creatinine assays

When it comes to assessing kidney function, measuring the glomerular filtration rate (GFR) accurately is essential. At the heart of this measurement lies serum creatinine — but not all creatinine assays are created equal. If your lab is still using a non-compensated Jaffé method, it's time to rethink your approach.

Better accuracy starts with better methods

The non-compensated Jaffé method, while widely known, lacks the specificity required for high-quality results. It is susceptible to interferences from substances like glucose, proteins, and ketones — which can lead to overestimated creatinine levels and, ultimately, inaccurate GFR calculations.

This is where compensated Jaffé and enzymatic creatinine assays come into play.

Why traceability matters

Compensated Jaffé and enzymatic methods — like those offered by BioSystems — are traceable to the SRM967 reference material certified by the National Institute of Standards and Technology (NIST). This traceability guarantees:

Metrological consistency: Results are comparable across different labs and over time.
Reliable GFR estimates: Essential for applying standardized equations like MDRD and CKD-EPI.
Better clinical decisions: Accurate results mean clinicians can more confidently stage chronic kidney disease and tailor treatments effectively.

In contrast, non-compensated Jaffé methods are not traceable to SRM967, putting labs at risk of reporting misleading data — and potentially compromising patient care.

Business advantages for your lab

Switching to enzymatic or compensated Jaffé methods is not just a scientific upgrade — it's a strategic move. Here’s why:

Build trust with clinicians by providing them with more accurate and standardized results.
Stay compliant with evolving clinical guidelines that increasingly emphasize traceability and accuracy.
Differentiate your lab in a competitive market by offering reliable kidney function testing.

Reduce the risk of costly re-tests or misdiagnoses, saving time and protecting your reputation.

The BioSystems advantage

BioSystems' enzymatic and compensated Jaffé assays are both SRM967-traceable, offering the reliability and quality that modern labs and healthcare provider’s demand. We help you deliver the best creatinine analysis in serum samples — and stand out in the market.

Ready to upgrade?

Let’s talk about how BioSystems can support your transition to SRM967-traceable creatinine testing — and help your lab deliver results clinicians can trust.